| 查看: 791 | 回复: 16 | |||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
英语翻译
|
|||
|
Dose response studies The Applicant has presented two phase 2 studies for the claimed indications (for cSSTI: Study 200 and for cIAI: Study 202). Study 200 was a randomized, open-label, comparison study of hospitalized subjects with complicated Skin and Soft Tissue infections in which 160 patients received either tigecycline 25 or 50 mg twice daily with an initial dose of 50 or 100 mg, respectively. The clinical data from this study indicated a trend toward a dose-related clinical cure response (67% and 74%, respectively) and dose-related pathogen eradication (56% and 70%). Also dose-safety relationships appeared evident for the adverse events (AEs) of nausea (22% and 35%) and vomiting (13% and 18%). Since tigecycline is intended for use in complicated infections, efficacy was favoured in benefit/risk -balance, and the greater dosage schedule (50 mg twice daily with an initial dose of 100 mg) was used in all consecutive clinical Phase II and III trials. Study 202 was a phase 2, multicenter, open-label study in hospitalized subjects with complicated intra-abdominal infections in which 111 subjects received an initial IV loading dose of 100 mg of tigecycline followed by 50 mg every 12 hours. Treatment continued for at least 5 days but not more than 14 days. There were no comparator or placebo groups. Overall, it appears that the choice of the dosage regimen for phase 3 studies is based on pharmacokinetic considerations as well as tolerability. The safety profile in these phase 2 studies is consistent with that seen in the larger database of phase 3 clinical trials. However, it should be highlighted that one case of Clostridium difficile associated colitis has been reported in Study 202. Apparently, this was the only one serious case reported of this adverse event for subjects in Phase 2 and 3 trials. Complicated intra-abdominal infections (cIAI) Methods Two pivotal phase 3 trials (studies 301 and 306) have been submitted in support of the indication complicated intra-abdominal infections. Study 301 was carried out in the Western hemisphere, and 306 in worldwide. The study protocols were similar in all essential points. Both phase 3 were multicenter, double-blind (third-party unblinded) studies in which 1568 hospitalised patients (approximately 800 patients per trial) with complicated intra-abdominal infections who were candidates for or had received a laparotomy, laparoscopy, or percutaneous drainage of an intraabdominal abscess were randomized. Key inclusion criteria were the followings: 1. Hospitalized male or female subjects, at least 18 years of age. 2. Candidate for, or had, a laparotomy, laparoscopy, or percutaneous drainage of an intra-abdominal abscess. 3. Complicated intra-abdominal infection, such as: a. An intra-abdominal abscess. b. An intra-abdominal abscess (including liver and spleen) that developed in a postoperative subject who received more than 48 hours but not more than 5 days of a nonstudy antibiotic and an intraabdominal culture was obtained from the infected site. c. Appendicitis complicated by perforation (grossly visible) and abscess or periappendicular abscess. d. Perforated diverticulitis complicated by abscess formation or faecal contamination. e. Complicated cholecystitis with evidence of perforation or empyema. f. Perforation of the large or small intestine with abscess or fecal contamination. g. Purulent peritonitis or peritonitis associated with faecal contamination. h. Gastric or duodenal ulcer perforation with symptoms lasting at least 24 hours before operation. i. Traumatic bowel perforation with symptoms lasting at least 12 hours before operation. 4. No more than 1 dose of an antibiotic (single broad-spectrum agent or 1 dose of each antibiotic in a combination regimen such as metronidazole, ampicillin,gentamicin) after the baseline intra-abdominal culture was obtained from the infected site. [ Last edited by 痴夷子皮 on 2011-1-10 at 13:07 ] |
回复此楼» 猜你喜欢
收到复试调剂但是去不了
已经有7人回复
-
260求调剂
已经有5人回复
-
急需调剂
已经有10人回复
-
申博/考博
已经有4人回复
-
化工学硕294分，求导师收留
已经有37人回复
-
求调剂
已经有11人回复
-
一志愿华中农业071010，320求调剂
已经有19人回复
-
304求调剂
已经有7人回复
-
求博导｜生物质基多孔碳/超级电容方向，已有相关成果，寻能源材料/碳材料方向老师
已经有3人回复
-
二苯甲酮酸类衍生物
已经有6人回复
» 抢金币啦！回帖就可以得到:
-
青岛大学/康复大学导师课题组2026年博士研究生
+3/353
-
厦门华侨大学就读的泰国排名第一世界排名221位朱拉隆功大学学位正式招生了
+1/87
-
长江大学化工学院环境学硕、专硕最后一批调剂（理学、工学均可，线上面试）
+1/83
-
重庆大学刘坤教授课题组招聘等离子体农业应用相关方向科研助理（农学、等离子体、电子
+1/82
-
森林工程课题组招调剂学术型硕士研究生，机不可失，期待您的加入。
+1/37
-
成都大学药学院-药学1055专硕：新导师开山弟子火热招募中
+1/37
-
江西科技师范大学086生物与医药
+1/37
-
盐城师范学院生物与医药（生物技术与工程领域）还有调剂名额
+1/36
-
桂林理工大学物理学专业招收调剂
+1/33
-
西工大国家级青年人才招聘微尺度传热方向博士后/研究助理
+1/33
-
致中山白雪：于法理与人间，赴一场双向奔赴
+1/30
-
佛山大学 动物科技学院 畜牧 欢迎广大学子报考！调剂名额若干
+1/9
-
北化大学材料科学与工程学院研究生调剂
+1/8
-
佛山大学动物科技学院2026年硕士研究生招生调剂公告（第三批）
+1/8
-
南京林业大学-国家级青年人才团队 诚聘青年教授、博士后等青年才俊
+1/8
-
华南师范大学环境学院大分子体系多尺度模拟与实验研究团队招收2026年考研调剂生1名
+1/5
-
2026年中国劳动关系学院环境与资源（安全工程领域）专业硕士研究生调剂复试（第三轮）
+1/3
-
福建理工大学学硕08开头还有调剂名额
+1/2
-
测试储氢合金的氢气渗透率
+1/2
-
河南城建学院生命科学与工程学院诚招工学专硕，接受跨专业调剂
+1/2
15楼2011-01-12 11:59:17
5楼2011-01-10 13:31:48
6楼2011-01-10 13:37:57
7楼2011-01-10 13:40:17
